



#13/K.T.
4/23
Revoc.
ISPH-0596 w/p.o.a

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of) Group Art Unit: 1635
Crooke et al.) Examiner: J. Schultz
Appln No. 09/925,139)
Filed: August 8, 2001)
For: ANTISENSE MODULATION OF)
CHOLESTEROL ESTER TRANSFER)
PROTEIN EXPRESSION)

Commissioner for Patents
Washington, D. C. 20231

RECEIVED
APR 16 2003
TECH CENTER 1600/2900

POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST AND
REVOCATION OF PRIOR POWERS AND STATEMENT UNDER
37 CFR §3.73(b)

Sir:

As assignee of record of the entire interest of the
above-identified application, ISIS PHARMACEUTICALS, INC.
hereby revokes all powers of attorney previously given.

ISIS PHARMACEUTICALS, INC. hereby appoints the
following attorney(s) and/or agent(s) to prosecute and
transact all business in the United States Patent and
Trademark Office connected with the above-identified
application: Stanley B. Kita, Registration No. 24,561;
George A. Smith, Jr., Registration No. 24,442; Mary E.

Certificate of Mailing under 37 CFR Section 1.8

I hereby certify that this correspondence is being deposited with the United States
Postal Service with sufficient postage as first class mail in an envelope addressed to
Commissioner for Patents, Washington, DC 20231 on April 9, 2003.

Diana M. Waligun Date
Signature
Diana M. Waligun
Typed or Printed Name of Person Signing Certificate

Bak, Registration No. 31,215; Cathy A. Kodroff, Registration No. 33,980; William Bak, Registration No. 37,277; Tracy U. Palovich, Registration No. 47,840; all of the firm of HOWSON AND HOWSON, of Spring House, Pennsylvania; and

Herb Boswell, Registration No. 27311; Laurel S. Bernstein, Registration No. 37,280; Neil S. Bartfield, Registration No. 39,901; Matthew Grumbling, Registration No. 44,427; Donna T. Ward, Registration No. 48,271, all of ISIS PHARMACEUTICALS, INC., of Carlsbad, California.

Address all telephone calls to Mary E. Bak at telephone No. (215) 540-9206. Address all correspondence to HOWSON AND HOWSON, Spring House Corporate Center, Box 457, Spring House, Pennsylvania 19477.

ISIS PHARMACEUTICALS, INC. certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of an assignment from the inventors.

The evidentiary documents relating to the ownership of the above-identified application and the invention claimed therein have been reviewed, and consist of an assignment of the above-identified United States Patent Application No. 09/925,139 from the inventors to ISIS PHARMACEUTICALS, INC. The assignment was recorded at Reel 012595 and Frame 0200, and Reel 012596 and Frame 0278, on February 4, 2002 at the United States Patent and Trademark Office.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above, and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned is empowered to sign this certificate on behalf of the assignee. To the best of the undersigned's knowledge and belief, title is solely in the assignee ISIS PHARMACEUTICALS, INC.


I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made, are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, or any patent issuing thereon.

ISIS PHARMACEUTICALS, INC.

DATE

4/4/03

BY



B. Lynne Parshall
Executive Vice President